Cooperative Agreement U01CA305105
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $851K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Texas, USA
Similar Awards
- This Cooperative Agreement award of $922,755.00 from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) supports research at the University of Massachusetts Medical School (UMASS Medical) aimed at understanding the role of tRNA modification and translational remodeling in cancer progression and metastasis. The project will use advanced RNA mass spectrometry, sequencing, and ribosome profiling techniques to comprehensively catalog tRNA modification dynamics...
- This $521,579 Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research to identify critical regulators controlling clear cell renal cell carcinoma (CCRCC) lung metastasis. The University of Texas Southwestern Medical Center, the awardee, will conduct a genome-wide CRISPR screen to characterize the role of the hepatic leukemia factor (HLF) in CCRCC lung metastasis and examine the underlying molecular...
- This Cooperative Agreement award for $639,882, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research at the University of North Carolina at Chapel Hill to elucidate the molecular mechanisms of metastasis organ tropism in breast cancer. The key objectives are to: Identify molecular determinants of lung and liver organ-specific metastasis using a comprehensive dataset of human primary tumors and metastases, as well as genetically...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to understand how cancer stem cells can transfer their mitochondria to macrophages, and how this mitochondrial transfer can reprogram the macrophages to support cancer growth and spread. The $161,794 award to Texas Tech University System will test the reproducibility of this mitochondrial transfer process across different cancer types, and determine if it is an active or passive...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $544,478 to The University of Texas Southwestern Medical Center to conduct research on "Decoding the Metabolic Routes of Purine Nucleotides in Cancer". The overarching goal is to expand the mechanistic understanding of purine synthesis pathways in tumors and identify new strategies to target purine supply mechanisms for effective cancer treatment. Key research aims include:...
- This federal Project Grant award of $323,700.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the University of Texas Southwestern Medical Center to identify critical regulators for clear cell renal cell carcinoma (ccRCC) using enhancer CRISPR screening. The research project aims to enhance understanding of cellular mechanisms involved in ccRCC, with the goal of developing innovative medical...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $999,096.00 to The University of Texas Southwestern Medical Center to conduct research on "Targeting DNA Damage Response to Treat Clear Cell Renal Cell Carcinoma." The award period runs from July 1, 2024 to June 30, 2028. The research aims to develop new treatments for clear cell renal cell carcinoma, a type of kidney cancer, by investigating...
- The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Texas at Austin (UT Austin) for $140,328.00. The award period runs from December 17, 2024 to August 15, 2027. The project aims to engineer a stable, high-affinity human methylthioadenosine phosphorylase enzyme that can degrade both adenosine and 5'methylthioadenosine in the tumor microenvironment. This enzyme-mediated depletion of these immunosuppressive...
- This $150,104 federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) to Yale University supports research to determine the regulatory role of dose-sensitive 5-methylcytosine (m5C) modifications on mRNA translation initiation and their impact on cancer. The project aims to screen approximately 35,000 human 5' untranslated regions (5'-UTRs) for m5C installation by the methyltransferases NSUN2 and NSUN6, and quantify ribosome recruitment to these...
- This $1,565,298.00 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by The University of Texas Health Science Center at San Antonio to target the METTL3 enzyme in order to overcome drug resistance in metastatic clear cell renal cell carcinoma. The project aims to develop innovative medical solutions to address this critical health challenge for military personnel and the broader public. The award period runs...